BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global leader in oncology, has unveiled new findings from the SEQUOIA study of BRUKINSA® (zanubrutinib) today at EHA2024 in Madrid, Spain.…
Kirin Holdings Company, Limited (Kirin Holdings) (TOKYO: 2503) has announced its intention to acquire additional shares of common stock of FANCL Corporation (FANCL) (TOKYO: 4921) through a tender offer and…
Enveda Biosciences Secures $55M to Advance AI-Driven Drug Development Enveda Biosciences, known for its pioneering use of AI in drug discovery, has announced a $55 million financing round. This round,…
WHO remains concerned about the escalating health crisis in the occupied Palestinian territory, including the West Bank, where attacks on health infrastructure and increased restrictions on movement are obstructing access…
The World Health Organization has released a new guideline outlining effective strategies to foster food environments that support healthy dietary choices. Emphasizing fiscal policies as a pivotal tool, the guideline…
WHO Releases Latest Report on Antibacterial Development The World Health Organization (WHO) has published its most recent assessment of antibacterial agents, encompassing antibiotics in various stages of clinical and preclinical…
Zimbabwe has reached maturity level 3 (ML 3) in the WHO’s classification of regulatory authorities for medicines, marking a significant achievement in healthcare infrastructure. This classification, assessed using WHO’s Global…
Today, Takeda has announced a significant step forward in its oncology portfolio with the signing of an option agreement with Ascentage Pharma. This agreement paves the way for Takeda to…
Today, Vertex announced longer-term data for CASGEVY™ (exagamglogene autotemcel [exa-cel]) from global clinical trials involving individuals with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, presented…
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for Augtyro™ (repotrectinib) for treating adult and pediatric patients (12 years and older) with solid tumors that have a…
Today, the U.S. Food and Drug Administration (FDA) approved BLINCYTO® (blinatumomab) for treating adult and pediatric patients (one month or older) with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia…
Today, detailed overall survival (OS) results from the Phase 2 MagnetisMM-3 study of ELREXFIO™ (elranatamab-bcmm) in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) were announced. The study…